# US 2019/0167599 A1 · Soft gelatin encapsulated pharmaceutical composition of cis-5,8,11,14,17-eicosapentaenoic acid in free acid form and cis-7,10,13,16,19-docosapentaenoic acid in free acid form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167599 A1
- Document ID: US20190167599A1
- Status: Published application
- Kind: A1
- Application number: 16/256,709
- Filed: 2019-01-24
- Published: 2019-06-06
- Earliest claimed: 2012-09-13
- Assignees: Chrysalis Pharma AG
- Applicants: Chrysalis Pharma AG
- Inventors: Johannes SPLEISS
- Web page: https://patentgrep.com/patent/US20190167599A1

## CPC

- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61P 3/06: Antihyperlipidemics
- A61P 11/06: Antiasthmatics
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim at position 2

38: A soft gelatin capsule, comprising:
a soft gelatin shell encapsulating a pharmaceutical formulation,
wherein the pharmaceutical formulation comprises polyunsaturated fatty acids (PUFAs) in free acid form including
cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount of from 45 wt % to 65 wt % of the pharmaceutical formulation,
cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount of from 1 wt % to 75 wt % of the pharmaceutical formulation,
cis-4,7,10,13,16,19-docosahexaenoic acid (C22:6 n-3; “DHA”) in free acid form in an amount of from about 15 wt % to about 25 wt % of the pharmaceutical formulation, and
at least one omega-6 PUFA in free acid form,
wherein the total combined amount of omega-6 PUFAs in free acid form is no more than 10 wt %,
wherein the amount of all PUFAs in said pharmaceutical formulation does not exceed 100 wt %,
wherein the soft gelatin shell comprises a gelatin component made up of porcine Type A gelatin and a Type B gelatin, and
wherein the porcine Type A gelatin is present in an amount of no more than about 75 wt % of the gelatin component.

### Claim at position 3 (depends on 38)

39: The soft gelatin capsule as claimed in claim 38, wherein
the porcine Type A gelatin is present in an amount of no more than about 50 wt % of said gelatin component.

### Claim at position 4 (depends on 38)

40: The soft gelatin capsule as claimed in claim 38, wherein
the porcine Type A gelatin is present in an amount of no less than about 10 wt % of the gelatin component.

### Claim at position 5 (depends on 38)

41: The soft gelatin capsule as claimed in claim 38, wherein
the porcine Type A gelatin is present in an amount of no less than about 25 wt % of the gelatin component.

### Claim at position 6 (depends on 38)

42: The soft gelatin capsule as claimed in claim 38, wherein
the Type B gelatin is bovine Type B gelatin.

### Claim at position 7 (depends on 38)

43: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of at least 2 wt %.

### Claim at position 8 (depends on 38)

44: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of at least 3 wt %.

### Claim at position 9 (depends on 38)

45: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of at least 4 wt %.

### Claim at position 10 (depends on 38)

46: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present the pharmaceutical formulation in an amount of no more than about 50 wt %.

### Claim at position 11 (depends on 38)

47: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of no more than about 25 wt %.

### Claim at position 12 (depends on 38)

48: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of no more than about 10 wt %.

### Claim at position 13 (depends on 38)

49: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of no more than about 8 wt %.

### Claim at position 14 (depends on 38)

50: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of from about 3 wt % to about 7 wt %.

### Claim at position 15 (depends on 38)

51: The soft gelatin capsule as claimed in claim 38, wherein
the DPA in free acid form is present in the pharmaceutical formulation in an amount of from about 4 wt % to about 6 wt %.

### Claim at position 16 (depends on 38)

52: The soft gelatin capsule as claimed in claim 38, wherein
the pharmaceutical formulation comprises EPA in free acid form and DHA in free acid form in a total combined amount of from about 60 wt % to about 90 wt % of the pharmaceutical formulation.

### Claim at position 17 (depends on 38)

53: The soft gelatin capsule as claimed in claim 38, wherein
the pharmaceutical formulation comprises at least one further omega-3 PUFA in free acid form.

### Claim at position 18 (depends on 53)

54: The soft gelatin capsule as claimed in claim 53, wherein
the at least one further omega-3 PUFA is selected from the group consisting of α-linolenic acid (C18:3 n-3); moroctic acid (C18:4 n-3); eicosatetraenoic acid (C20:4 n-3); heneicosapentaenoic acid (C21:5 n-3); and eicosatrienoic acid (C20:3 n-3).

### Claim at position 19 (depends on 38)

55: The soft gelatin capsule as claimed in claim 38, wherein
the total combined amount of omega-3 PUFAs in free acid form in the pharmaceutical formulation is from about 80 wt % to about 95 wt % of said formulation.

### Claim at position 20 (depends on 38)

56: The soft gelatin capsule as claimed in claim 38, wherein
the at least one omega-6 PUFA is selected from the group consisting of dihomo-gamma-linolenic acid (C20:3 n-6); arachidonic acid (C20:4 n-6); linoleic acid (C18:2 n-6); docosapentaenoic acid (C22:5; n-6); gamma-linolenic acid (C18:3 n-6); and eicosadienoic acid (C22:2 n-6).

### Claim 57 (depends on 38)

The soft gelatin capsule as claimed in claim 38, encapsulating from about 100 mg to about 2000 mg of the pharmaceutical formulation.

### Claim at position 22 (depends on 38)

58: The soft gelatin capsule as claimed in claim 38, wherein
the capsule is coated with a polymeric film coating to control release of the pharmaceutical formulation in the intestines.

### Claim at position 23 (depends on 38)

59: A process for manufacturing a soft gelatin capsule according to claim 38, said process comprising encapsulating said pharmaceutical formulation in said soft gelatin shell.

### Claim at position 24 (depends on 38)

60: A method of treatment or prophylaxis of a condition, said method comprising:
administering a therapeutically effective amount of at least one soft gelatin capsule according to claim 38 to a subject in need thereof;
wherein said condition is at least one selected from the group consisting of chronic inflammatory conditions, hyperlipidaemia, hypertriglyceridaemia, asthma, bipolar disorder, and neoplastic disease.

### Claim at position 25

61: A soft gelatin capsule, comprising:
a soft gelatin shell encapsulating a pharmaceutical formulation,
wherein the pharmaceutical formulation comprises polyunsaturated fatty acids (PUFAs) in free acid form including
cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form amount of from 45 wt % to 65 wt % of the pharmaceutical formulation,
cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount of from 1 wt % to 75 wt % of the pharmaceutical formulation,
cis-4,7,10,13,16,19-docosahexaenoic acid (C22:6 n-3: “DHA”) in free acid form in an amount of from about 15 wt % to about 25 wt % of the pharmaceutical formulation, and
at least one omega-6 PUFA in free acid form,
wherein the total combined amount of omega-6 PUFAs in free acid form is no more than 10 wt %,
wherein the amount of all PUFAs in said pharmaceutical formulation does not exceed 100 wt %,
wherein the soft gelatin shell comprises a gelatin component made up of porcine Type A gelatin and a Type B gelatin, and
wherein the porcine Type A gelatin is present in an amount of no less than about 10 wt % to no more than about 75 wt % of the gelatin component.

### Claim at position 26

62: A soft gelatin capsule, comprising:
a soft gelatin shell encapsulating a pharmaceutical formulation,
wherein the pharmaceutical formulation comprises polyunsaturated fatty acids (PUFAs) in free acid form including
cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form amount of from 45 wt % to 65 wt % of the pharmaceutical formulation,
cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount of from 1 wt % to 75 wt % of the pharmaceutical formulation,
cis-4,7,10,13,16,19-docosahexaenoic acid (C22:6 n-3; “DHA”) in free acid form in an amount of from about 15 wt % to about 25 wt % of the pharmaceutical formulation, and
at least one omega-6 PUFA in free acid form,
wherein the total combined amount of omega-6 PUFAs in free acid form is no more than 10 wt %
wherein the amount of all PUFAs in said pharmaceutical formulation does not exceed 100 wt %,
wherein the soft gelatin shell comprises a gelatin component made up of porcine Type A gelatin and a Type B gelatin, and
wherein the porcine Type A gelatin is present in an amount of no less than about 0.5 wt % to no more than about 75 wt % of the gelatin component.